Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Mutations in RNA splicing factors (SFs) are common in leukemias and solid tumors.
• Cancer cells with SF mutations often depend on normal splicing for survival.
• Clinical strategies are exploring spliceosome inhibition for refractory leukemias.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting protein arginine methyltransferases (PRMTs) in SF-mutant cancers.
• To determine if PRMT inhibition preferentially affects SF-mutant leukemias compared to wild-type counterparts.
• To elucidate the mechanistic basis for PRMT inhibition's efficacy in cancer treatment.

Main Methods:

• Inhibition of symmetric dimethylation via PRMT5.
• Inhibition of asymmetric dimethylation via type I PRMTs.
• Assessment of splicing fidelity and cell viability in SF-mutant and wild-type leukemia models.

Main Results:

• Inhibiting PRMT5 or type I PRMTs reduces RNA splicing fidelity.
• PRMT inhibition leads to preferential killing of SF-mutant leukemias over wild-type cells.
• Combined PRMT5 and type I PRMT inhibition shows synergistic effects.

Conclusions:

• PRMT inhibition represents a promising therapeutic strategy for cancers with SF mutations.
• Identifies specific genetic subsets of cancer likely to respond to PRMT inhibitors.
• Provides a mechanistic understanding of PRMT inhibition's anti-cancer effects.